Close-up of sample being place into microplate

David Chen Lab

Epigenetic dysregulation plays an important role in cancer initiation, progression and therapeutic responses. Dr. Chen's research goal is to provide novel and more effective cancer therapies by understanding how epigenetic regulators control oncogene expression under normal and malignant conditions.
Research Lab Overview

  The long-term goal of Dr. Chen’s laboratory in the Department of Systems Biology is to provide novel opportunities for advanced leukemia/cancer therapies by understanding how genetic/epigenetic regulators and their networks control gene expression, epigenetic landscape, and genome integrity under normal and disease conditions. His prior study based on a genome-wide functional genomic screen has identified cross-inhibitory genetic interactions between multiple chromatin effectors in MLL-r leukemias, a highly malignant disease that affects about 50% of infant acute leukemia patients (and nearly 10% of the acute leukemia in all patients). These results have been published in Nature Medicine (Chen et al. 2015) and have led his current research towards combinational therapies for multiple types of malignant diseases. His recent publications include Molecular Cell (2015, 2017, 2021), Cell (2018), Blood (2019, 2019, 2020, 2021, 2022), Genes and Development (2019), Science Translational Medicine (2019), Front Cell Dev Biol (2019*), Journal of Clinical Investigation (2016, 2022), Cell Stem Cell (2020), Cells (2020*), Nature (2020, 2020), Cancer Discovery (2016, 2020), Leukemia (2022*), Nature Cell Biology (2022) and Nature Communications (2021*, 2022). Dr. Chen also leads technological development and pioneered a single-cell CRISPR gene tiling pipeline “sc-Tiling” for structural/functional genomics and therapeutic pocket discovery (Yang et al. 2021, Nature Communications*). 

   Dr. Chen’s research program is funded by several NIH (R37 MERIT, R01, K99/R00) and foundation (ASH Scholar, ALSF Innovation) awards. He also supports consortium research efforts including a NIH/NCI U54 FusOnC2 (PI: Charles Mullighan; St. Jude Children’s Hospital) and a SU2C-CRUK Pediatric Cancer New Discoveries Challenge.

myNCBI: https://www.ncbi.nlm.nih.gov/myncbi/1rQtkueF6vPQu/bibliography/public/
 

Principal Investigator: Chun-Wei (David) Chen, Ph.D.

As an Associate Professor of Department of Systems Biology and Member of City of Hope Comprehensive Cancer Center, David Chen also serves as Director of Division of Epigenetics and Transcriptional Engineering at City of Hope. His lab focuses on epigenetic mechanisms, drug resistance, and therapeutic target discovery in cancers using high throughput genetic screens.

Full bio
David Chen, Ph.D.
Lab Members
Anthony Chan
Anthony Chan, Ph.D.
Staff Scientist
Research Focus Molecular cell biology and epigenetics in cancer research Therapeutic target discovery using high-throughput CRISPR genetic screens Drug discovery using a combination of in silico modeling, in vitro binding assays, and cell-based methods Full Bio
Shai Izraeli
Shai Izraeli, M.D.
Research Professor
Research Focus Hematologic malignancies Cancer predisposition syndromes Centrosomal biology and chromosomal aneuploidy and its roles in developmental biology and cancer Full bio
Mingli Li
Mingli Li, Ph.D.
Postdoctoral Fellow
Research Focus Molecular cell biology and biochemistry in cancer research Drug discovery using cell-based disease model screening Identification of novel therapeutic targets to eliminate cancer cells Full bio
Nicole Mattson
Nicole Mattson, B.S.
Graduate Student
Research Focus High throughput CRISPR screens for identification of essential surface proteins in breast cancer Nicole Mattson received her B.S. in biology with a focus in molecular biology and a minor in biotechnology from Santa Clara University in 2016. In June 2016, she joined the Vaccines Immunotherapy department at Pfizer in La Jolla, California, working on novel cancer therapeutics. In August 2018, Mattson started her graduate education at the Irell & Manella Graduate School of Biological Sciences at City of Hope. In July 2019, she joined the David Chen Lab in the Department of Systems Biology. Her research is focused on using high throughput CRISPR screens to identify essential genes on the surface of cancer cells. Her ultimate goal is to discover novel therapeutics to target identified genes. Degrees 2016, B.S. Biology, Minor Biotechnology, Santa Clara University, Santa Clara, CA
Sheela Pokharel
Sheela Pangeni Pokharel, M.S.
Research Associate II
Clinical Expertise Genotyping DNA/RNA/plasmid DNA extraction/preparation CRISPR library cloning Degrees 2015, M.S., Applied Microbiology and Biotechnology, University of Wolverhampton, England, United Kingdom 2009, B.S., Microbiology, Tribhuvan University, Kathmandu, Nepal Professional Experience 2017-present, Research Associate II, City of Hope Beckman Research Institute, Monrovia, CA 2016-2017, Research Technologist II, Northwestern University, Chicago, IL
Priyanka Singh, Ph.D. | Postdoctoral Fellow | Monrovia, CA | Beckman Research Institute of City of Hope
Priyanka Singh
Postdoctoral Fellow
Dr. Priyanka Singh obtained her Ph.D. from the Post Graduate Institute of Medical Education and Research, India. She is experienced in epigenetics and molecular biology techniques which help find new treatments for cancer patients. Dr. Singh joined David Chen’s laboratory at the Department of Systems Biology in March 2022. Her current projects focus on identifying novel therapeutic targets in leukemia using genetic and epigenetic approaches using CRISPR-based systems. Research Focus Investigation and identification of genes related to epigenetics in leukemia using CRISPR library screening Degrees 2015-2020, Ph.D., Post Graduate Institute of Medical Education and Research, Chandigarh, India 2010-2012, M.Sc. (Hons), Biochemistry, Panjab University, Chandigarh, India 2007-2010, B.Sc. (Hons), Biochemistry, Panjab University, Chandigarh, India Fellowships 2022-present, Fellowship, Department of Systems Biology, City of Hope Beckman Research Institute, Monrovia, CA 2015-2020, Junior and Senior Research Fellowship, Indian Council of Medical Research, India 2014, National Eligibility Test-Lectureship, Council of Science and Industrial Research, India Professional Experience 2022-present, Postdoctoral Fellow, Beckman Research Institute of City of Hope, Monrovia, CA 2021-2022, Research Associate, National Institute of Malaria Research-ICMR, New Delhi, India 2015-2020, Ph.D. Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India Awards 2020, Second Prize in Oral Presentation in Indian Society for Bone and Mineral Research, India 2020, Travel Award (ECTS-East meets West award) European Calcified Tissue Society, France (virtual event) 2020, Young Investigator Emerging Country Award, American Society of Bone and Mineral Research (virtual event) 2019, First prize in oral presentation in Indian Society for Bone and Mineral Research, Bangalore, India 2018, YUVA scholarship, NextGen Genomics, Biology, Bioinformatics and Technologies Conference, Jaipur, India 2018, Women in Endocrinology “Young Investigator Award," ENDO US, Chicago, IL 2016, Young Investigator Award, International Osteoporosis Foundation Meeting, Singapore Memberships Member of Indian Society of Bone and Mineral Research (ISBMR), India Publications Singh, P., Bhadada, S.K., Dahiya, D., Arya, A.K., Saikia, U.N., Kaur, J., Sachdeva, N., Behera, A., Brandi, M.L., & Rao, S.D. GCM2 Silencing in Parathyroid Adenoma is associated with Promoter Hypermethylation and Gain of Methylation on Histone 3, Journal of Clinical Endocrinology and Metabolism. 2021 Singh, P., Bhadada, S.K., Arya, A.K., Saikia, U.N., Dahiya, D., Kaur, J., Sachdeva, N., Brandi, M.L., & Rao, S.D. Aberrant epigenetic alteration of PAX1 expression contributes to parathyroid tumorigenesis. Journal of Clinical Endocrinology and Metabolism. 2021 Singh, P., Bhadada, S.K., Dahiya, D., Arya, A.K., Saikia, U.N., Kaur, J., Sachdeva, N., Brandi, M.L., & Rao, S.D., Reduced Calcium Sensing Receptor is Epigenetically Inactivated in Parathyroid Adenomas. Journal of Clinical Endocrinology and Metabolism. 2020 Arya, A.K., Kumari, P., Bhadada, S.K., Agrawal, K., Singh, P., Mukherjee, S., Sood, A., & Rao, S.D. Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry. J Bone Miner Metab. 2020 Pal, R., Arya, A.K., Aggarwal, A., Singh, P., Dahiya, D., Sood, A., Singh, T., Ram, S., Bhansali, A., & Bhadada, S.K. Weight gain after curative parathyroidectomy predicts increase in bone mineral density in patients with symptomatic primary hyperparathyroidism. Clin Endocrinol (Oxf). 2020 Singh, P., Vadi, S.K., Saikia, U.N., Sood, A., Dahiya, D., Arya, A.K., Behera, A., Mukherjee, S., Arvindkumar, S.M., & Bhadada, S.K. Minimally invasive parathyroid carcinoma-A missing entity between parathyroid adenoma and carcinoma: Scintigraphic and histological features. Clinical Endocrinology (Oxf). 2019 Arya, A.K., Bhadada, S.K., Singh, P., Sachdeva, N., Saikia, U.N., Dahiya, D., Behera, A., Bhansali, A., & Rao, S.D., Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas. Sci Rep. 2017
Xiaobao Xu
Xiaobao Xu, Ph.D.
Postdoctoral Fellow
Research Focus Precision medical with single cell detection and imaging Investigation of epigenetics by using CRISPR-CAS9 Immunotherapy and mechanism of immune system respond to inflammation Dr. Xiaobao Xu obtained his Ph.D. degree from Zhejiang University, China. He is experienced in biomimicry drug self-delivery system based on red blood cells membrane, and immunotherapy based on combined checkpoint inhibitor with thermal therapy. Dr. Xu joined David Chen’s laboratory at the Department of Systems Biology in January 2019. His current projects focus on developing novel CRISPR-based systems for epigenome editing and cancer therapy. Degrees 2014 - 2018, Ph.D., Biomedical Engineering, Zhejiang University, Hangzhou, P. R. China 2009 - 2012, M.S. Bioengineering, Guizhou University, Guiyang, P. R. China 2005 - 2009, B.S. Bioengineering, Guizhou University, Guiyang, P. R. China Fellowship 2019 – Current, Department of Systems Biology, City of Hope Beckman Research Institute, Monrovia, CA Professional Experience 2019 – present, Postdoctoral Fellow, Department of Systems Biology, City of Hope Beckman Research Institute, Monrovia, CA 2016-2018, Visiting Scholar, Department of Biochemistry and Molecular Medicine, Medical Center, University of California, Davis, CA 2014-2018, College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, P. R. China Publications Xu X, Yang G, Xue X, et al(2018). A polymer-free, biomimicry drug self-delivery system fabricated via a synergistic combination of bottom-up and top-down approaches[J]. Journal of Materials Chemistry B, 6(47): 7842-7853. XB. Xu, ed. Al. (2016) Metabolomic profile for the early detection of coronary artery disease by using UPLC-QTOF/MS.Journal of pharmaceutical and biomedical analysis, 129, 34-42. XB.Xu,TX.Wu,QL.Tang.(2016)ChangesinGastrodiatuber,EthanolExtracts During Grifola frondosa, Fermentation. Chemistry of Natural Compounds, 52(1):74-77. XD. Xue, Yee. Huang, RN. Bo, B. Jia, H. Wu, Y. Yuan, ZL. Wang, Z. Ma, D. Jing, XB. Xu, et al. (2018) Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment. Nature Communications, DOI: 10.1038/s41467-018-06093-5. W. Zhu, XB. Xu, JK. Tian, et al.(2015) Proteomic Analysis of Lonicera japonica Thunb. Immature Flower Buds using Combinatorial Peptide Ligand Libraries and Polyethylene Glycol Fractionation. Journal of Proteome Research.
Leisi Zhang | Visiting Scholar | Monrovia, CA | Department of Systems Biology
Leisi Zhang
Visiting Scholar
Research Focus Mechanisms underlying the therapeutic resistance in leukemia Education 2009-2017, M.D., Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China Professional Experience 2021-present, Visiting Scholar, Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, CA 2017-present, Internist, Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China Publications Zhang, L., Wang, J., Xu, M., Wu, T., Huang, S., Cao, H., Sun, A., Liu, S., & Xue, S. Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine. OncoTargets and therapy 2022, 15:159-164. Kong, J., Hao, Y., Wan, S., Li, Z., Zou, D., Zhang, L., Lu, Y., Wang, J., Chen, X., & Fu, J. Comparative study of hematological and radiological feature of severe/critically ill patients with COVID-19, influenza A H7N9, and H1N1 pneumonia, J Clin Lab Anal 2021 35(12):e24100. Yang, Q., Chen, K., Zhang, L., Feng, L., Fu, G., Jiang, S., Bi, S., Lin, C., Zhou, Y., Zhao, H., Chen, X., Fu, G. & Xu, B. Synthetic lethality of combined AT-101 with idarubicin in acute myeloid leukemia via blockade of DNA repair and activation of intrinsic apoptotic pathway. CANCER LETT 2019, 461: 31-43. Zhang, L., Zhou, Y., Chen, K., Shi, P., Li, Y., Deng, M., Jiang, Z., Wang, X., Li, P. & Xu, B. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. TARGET ONCOL 2017, 12(5): 677-687. Li, Y., Wang, Y., Zhou, Y., Li, J., Chen, K., Zhang, L., Deng, M., Deng, S., Li, P. & Xu, B. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells, Clinical Epigenetics, 2017.8, 9(83). Shi, P., Zhang, L., Chen, K., Jiang, Z., Deng, M., Zha, J., Guo, X., Li, P., & Xu, B. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage, Pharmacogenomics, 2017.8, 18(13): 1259~1270.
Join Our Team

Join one of our labs and help us on our mission to save lives.

View careers
Our Publications
DOT1L Inhibits SIRT1-mediated Epigenetic Silencing to Maintain Leukemic Gene Expression in MLL-rearranged Leukemia

C.W. Chen, R. Koche, A. Sinha, A. Deshpande, N. Zhu, R. Eng, J. Doench, H. Xu, S. Chu, J. Qi, X. Wang, C. Delaney, K.M. Bernt, D.E. Root, W.C. Hahn, J.E. Bradner, S.A. Armstrong. Nature Medicine. 2015, 21; 335-343. (IF = 53.440)

Drugging Chromatin in Cancer: Recent Advances and Novel Approaches

S.F. Cai, C.W. Chen, S.A. Armstrong. Molecular Cell. 2015, 60(4):561-70. (IF = 17.970)

NUP98-fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis

H Xu, D.G. Valerio, M.E. Eisold, A. Sinha, R.P. Koche, W. Hu, C.W. Chen, S.H. Chu, G.L. Brien, J.J. Hsieh, P. Ernst, S.A. Armstrong. Cancer Cell. 2016; 30(6):863-878. (IF = 31.743)

Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia

M.W. Kühn, E. Song, Z. Feng, A. Sinha, C.W. Chen,  A.J. Deshpande,  M. Cusan,  N. Farnoud,  A. Mupo,  C. Grove,  R. Koche,  J.E. Bradner,  E. de Stanchina,  G.S. Vassiliou,  T. Hoshii,  S.A. Armstrong. Cancer Discovery. 2016; 6(10):1166-1181. (IF = 39.397)

Modulation of Splicing Catalysis for Therapeutic Targeting of Leukemias with Spliceosomal Mutations

S.C.W. Lee, H. Dvinge, E. Kim, H. Cho, J.B Micol, Y.R. Chung, B.H. Durham, A. Yoshimi, Y.J. Kim, M. Thomas, C. Lobry, C.W. Chen, A. Pastore, J. Taylor, X. Wang, A. Krivtsov, S.A. Armstrong, J. Palacino, S. Buonamici, P.G. Smith, R.K. Bradley, O. Abdel-Wahab. Nature Medicine. 2016; 22(6):672-8. (IF = 53.440)

A UTX-MLL4-p300 Transcriptional Regulatory Network Coordinately Shapes Active Enhancer Landscapes for Eliciting Transcription

S.P. Wang, Z. Tang, C.W. Chen, M. Shimada, R.P. Koche, L.H. Wang, T. Nakadai, A. Chramiec, A.V. Krivtsov, S.A. Armstrong, R.G. Roeder. Molecular Cell. 2017; 67(2):308-321. (IF = 17.970)

A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response

T. Hoshii, P. Cifani, Z. Feng, C.H. Huang, R. Koche, C.W. Chen, C.D. Delaney, S.W. Lowe, A. Kentsis, S.A. Armstrong. Cell. 2018; 172(5):1007-1021.e17 (IF = 41.582)

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies

Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen C.W., Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW. Science Translational Medicine. 2019;11(511). (IF = 17.956)

RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia

Shen C, Sheng Y, Zhu AC, Robinson S, Jiang X, Dong L, Chen H, Su R, Yin Z, Li W, Deng X, Chen Y, Hu YC, Weng H, Huang H, Prince E, Cogle CR, Sun M, Zhang B, Chen C.W., Marcucci G, He C, Qian Z, Chen J. Cell Stem Cell. 2020. 27:1-17. (IF = 24.633)

Signaling input from divergent pathways subverts B cell transformation

Chan LN, Murakami MA, Robinson ME, Caeser R, Sadras T, Lee J, Cosgun KN, Kume K, Khairnar V, Xiao G, Ahmed MA, Aghania E, Deb G, Hurtz C, Shojaee S, Hong C, Pölönen P, Nix MA, Chen Z, Chen C.W., Chen J, Vogt A, Heinäniemi M, Lohi O, Wiita AP, Izraeli S, Geng H, Weinstock DM, Müschen M. Nature. 2020; 583(7818):845-851. (IF = 49.962)

Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition

Cai SF, Chu SH, Goldberg AD, Parvin S, Koche RP, Glass JL, Stein EM, Tallman MS, Sen F, Famulare CA, Cusan M, Huang CH, Chen C.W., Zou L, Cordner KB, DelGaudio NL, Durani V, Kini M, Rex M, Tian HS, Zuber J, Baslan T, Lowe SW, Rienhoff HY Jr, Letai A, Levine RL, Armstrong SA. Cancer Discovery. 2020; 10(10):1500-1513. (IF = 39.397)

IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells

Lee J, Robinson ME, Ma N, Artadji D, Ahmed MA, Xiao G, Sadras T, Deb G, Winchester J, Cosgun KN, Geng H, Chan LN, Kume K, Miettinen TP, Zhang Y, Nix MA, Klemm L, Chen C.W., Chen J, Khairnar V, Wiita AP, Thomas-Tikhonenko A, Farzan M, Jung JU, Weinstock DM, Manalis SR, Diamond MS, Vaidehi N, Müschen M. Nature. 2020; 588(7838):491-497. (IF = 49.962)

R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis

Qing Y, Dong L, Gao L, Li C, Li Y, Han L, Prince E, Tan B, Deng X, Wetzel C, Shen C, Gao M, Chen Z, Li W, Zhang B, Braas D, Ten Hoeve J, Sanchez GJ, Chen H, Chan LN, Chen C.W., Ann D, Jiang L, Müschen M, Marcucci G, Plas DR, Li Z, Su R, Chen J. Molecular Cell. 2021; 81(5):922-939. (IF = 17.970)

High-resolution characterization of gene function using single-cell CRISPR tiling screen

Yang L, Chan AKN, Miyashita K, Delaney CD, Wang X, Li H, Pokharel SP, Li S, Li M, Xu X, Lu W, Liu Q, Mattson N, Chen KY, Wang J, Yuan YC, Horne D, Rosen ST, Soto-Feliciano Y, Feng Z, Hoshii T, Xiao G, Müschen M, Chen J, Armstrong SA, Chen C.W.. Nature Communications. 2021; 12(1):4063. (IF = 14.919)

PLCG1 is required for AML1-ETO leukemia stem cell self-renewal

Schnoeder TM, Schwarzer A, Jayavelu AK, Hsu CJ, Kirkpatrick J, Döhner K, Perner F, Eifert T, Huber N, Arreba-Tutusaus P, Dolnik A, Assi SA, Nafria M, Jiang L, Dai YT, Chen Z, Chen SJ, Kellaway SG, Ptasinska A, Ng ES, Stanley EG, Elefanty AG, Buschbeck M, Bierhoff H, Brodt S, Matziolis G, Fischer KD, Hochhaus A, Chen C.W., Heidenreich O, Mann M, Lane SW, Bullinger L, Ori A, von Eyss B, Bonifer C, Heidel FH. Blood. 2022 Feb 17;139(7):1080-1097. (IF = 22.113)

3-Ketodihydrosphingosine reductase maintains ER homeostasis and unfolded protein response in leukemia

Liu Q, Chan AKN, Chang WH, Yang L, Pokharel SP, Miyashita K, Mattson N, Xu X, Li M, Lu W, Lin RJ, Wang SY, Chen C.W. Leukemia. 2022; 36(1):100-110. (IF = 11.528)

An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia

Geron I, Savino AM, Fishman H, Tal N, Brown J, Turati VA, James C, Sarno J, Hameiri-Grossman M, Lee YN, Rein A, Maniriho H, Birger Y, Zemlyansky A, Muler I, Davis KL, Marcu-Malina V, Mattson N, Parnas O, Wagener R, Fischer U, Barata JT, Jamieson CHM, Müschen M, Chen C.W., Borkhardt A, Kirsch IR, Nagler A, Enver T, Izraeli S. Nature Communications. 2022; 13(1):659. (IF = 14.919)

METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis

Su R, Dong L, Li Y, Gao M, He PC, Liu W, Wei J, Zhao Z, Gao L, Han L, Deng X, Li C, Prince E, Tan B, Qing Y, Qin X, Shen C, Xue M, Zhou K, Chen Z, Xue J, Li W, Qin H, Wu X, Sun M, Nam Y, Chen C.W., Huang W, Horne D, Rosen ST, He C, Chen J. Nature Cell Biology. 2022; 24(2):205-216. (IF = 28.824)

Disruption of dNTPs Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade

Wang H, He X, Zhang L, Dong H, Huang F, Xian J, Li M, Chen W, Lu X, Pathak KV, Huang W, Li Z, Zhang L, Nguyen LXT, Yang L, Feng L, Gordon D, Zhang J, Pirrotte P, Chen C.W., Salhotra A, Kuo YH, Horne DA, Marcucci G, Sykes DB, Tiziani S, Jin H, Wang X, Li L. Blood. 2022 Apr 19:blood.2021015108. Epub ahead of print. (IF = 22.113)

Degradation of GSPT1 causes TP53-independent cell death in leukemia whilst sparing normal hematopoietic stem cells

Sellar RS, Sperling AS, Słabicki M, Gasser JA, McConkey ME, Donovan KA, Mageed N, Adams DN, Zou C, Miller PG, Dutta RK, Boettcher S, Lin AE, Sandoval BE, Quevedo Barrios VA, Shkolnik V, Koeppel J, Henderson EK, Fink EC, Yang L, Chan AK, Pokharel SP, Bergstrom EJ, Burt R, Udeshi ND, Carr SA, Fischer ES, Chen C.W., Ebert BL. Journal of Clinical Investigation. 2022 Jun 28:e153514. doi: 10.1172/JCI153514. Epub ahead of print. (IF = 19.456)

View more
Research Highlights
High-throughput genetic screen pipeline:
research highlights

 

 

 

Single-cell CRISPR tiling scan:
David Chen research highlights
CRISPR multiomics:
David Chen research highlights
Lab News

2015
2015/03    David Chen received ASH/EHA TRTH Award

2016
2016/03    David Chen received NIH/NCI K99 Award
2016/06    David Chen appointed Instructor, Harvard Medical School
2016/12    David Chen presented at ASH (Best of ASH)

2017
2017/07    Grand opening – David Chen lab @ City of Hope
2017/07    David Chen appointed Assistant Professor, Systems Biology
2017/07    David Chen appointed Direct of Epigenetic and Transcriptional Engineering
2017/10    Welcome! Anthony Chan (postdoc)
2017/11    Welcome! Sheela Pangeni Pokharel (Lab manager)
2017/12    Welcome! Lu Yang (Research Assistant Professor; Bioinformatician)
2017/12    Welcome! Wen-Han Chang (postdoc)

2018
2018/04    Welcome! Kazuya Miyashita (postdoc)
2018/06    Welcome! Sandra Li (Roberts Summer Program)
2018/07    David Chen received ASH Scholar Award
2018/07    Steven Rosen (COH) received LLS Research Award (Chen: co-I)
2018/09    David Chen presented at Illumina Sequencing Innovation Symposium
2018/12    Steven Rosen (COH) received NIH/NCI R01 Award (Chen: co-I)
2018/12    David Chen presented at ASH
2018/12    Welcome! Mingli Li (postdoc)
2018/12    David Chen received NIH/NCI R37 MERIT Award

2019
2019/01    Welcome! Xiaobao Xu (postdoc)
2019/02    Welcome! Qiao Liu (PhD student)
2019/04    David Chen received NIH/NCI R01 Award
2019/05    Welcome! Nicole Mattson (PhD student)
2019/05    Anthony Chan (postdoc) published in Frontiers in Cell and Developmental Biology
2019/06    Welcome! Michelle Garcia (Pomona College/COH Intern Program)
2019/07    Welcome! Po-Wei Chiu (NTU/COH Summer Program)
2019/08    Welcome! Yi-Wei Chiang (MOST Scholarship)
2019/09    Charles Mullighan (St. Jude) received U54 Award (Chen leads Genome Core)
2019/10    David Chen received ALSF Innovation Award
2019/10    David Chen received COSF Research Award
2019/10    Welcome! Wei Lu (computational postdoc)
2019/12    David Chen presented at TRTH, ASH
2019/12    Anthony Chan (postdoc) presented at ASH

2020
2020/01    Kazuya Miyashita (postdoc) received Uehara Scholarship
2022/03    COVID lockdown till 2022/06
2020/03    David Chen appointed IBC member
2020/05    David Chen presented at Dana-Farber/Harvard Cancer Center (DF/HCC) Connect
2020/05    Michelle Garcia (Pomona College) received Caltech/Genentech WAVE Fellow
2020/08    Qiao Liu (PhD student) published in Cells
2020/08    David Chen received NIH/NCI ITCR Award

2021
2021/01    Alex Bishop (UTHSCSA) received SU2C-CRUK Award (Chen: co-I)
2021/01    Srividya Swaminathan (COH) received LLS Research Award (Chen: co-I)
2021/05    Michelle Garcia (Pomona College) received Goldwater Scholar
2021/06    David Chen presented at 10X Genomics CRISPR Functional Genomics Symposium
2021/06    Welcome! Renee Chen (CRISPR Summer Program)
2021/06    Welcome! Maggie Li (Roberts Summer Program)
2021/07    Lu Yang (Research Assistant Prof.) published in Nature Communications
2021/07    David Chen appointed NCI-I Study Section member
2021/09    David Chen presented at Genome Engineering Seminar, Harvard Medical School    
2021/10    Nicole Mattson (PhD student) received Payson Scholarship
2021/11    David Chen appointed Associate Professor, Systems Biology

2022
2022/01    Qiao Liu (PhD student) published in Leukemia
2022/03    Welcome! Priyanka Singh (postdoc)
2022/04    Mingli Li (postdoc) received AACR Scholar-in-Training Award
2022/04    Nicole Mattson (PhD student) received AACR Scholar-in-Training Award
2022/04    Xiaobao Xu (postdoc) presented at AACR
2022/04    Welcome! Leisi Zhang (postdoc)
2022/04    David Chen presented at The Science of Childhood Cancer Series, St. Jude
2022/05    David Chen appointed Associate Professor, Pediatrics (secondary appointment)
2022/06    Mingli Li (postdoc) received Sarcoma Foundation of America Award
2022/06    Mingli Li (postdoc) published in Biomedicines
2022/06    Welcome! Grace Aranda (CIRM Summer Fellow)
2022/07    Welcome! David Gomez-Novy (CRISPR Summer Program)
2022/08    Nicole Mattson (PhD student) received NIH/NCI F99 Award
 

Latest Research News
radiation stock
Mar. 6, 2023
Maxine Nunes
Novel radiation therapy zeros in on tough-to-treat cancers
City of Hope scientists have developed a remarkable new antibody with the unremarkable name M5A. It can precisely t...
Research
Breakthroughs
brain
Mar. 1, 2023
Maxine Nunes
Targeting glioblastoma with a cancer-killing virus
Glioblastoma is a virtually incurable brain cancer with a five-year-survival rate of only 10%. “It’s heartbr...
Research
Clinical Trials
Feb. 16, 2023
By Letisia Marquez
City of Hope Comprehensive Cancer Center earns highest ranking from National Cancer Institute
CONTACT Letisia Marquez 626-476-7593 lemarquez@coh.org • $23 million also awarded for research, training and c...
Press Release
View more
Contact Information

34.1293409, -117.971358

David Chen Lab
1500 East Duarte Road
Duarte, CA 91010
(626) 256-4673